Abstract | OBJECTIVE: SUMMARY OF BACKGROUND DATA: Although the development of multidrug chemotherapy regimens has improved the survival outcomes of patients with unresectable pancreatic cancer, the benefits of these treatments in the neo-adjuvant setting remain controversial. METHODS: RESULTS: Fifty-one patients were enrolled in this study [ FOLFIRINOX (n = 26) and GEM/nab-PTX (n = 25)]. A total of 84.3% (n = 43/51) of the patients eventually underwent surgery, and R0 resection was achieved in 67.4% (n = 33/ 51) of the patients. Adverse events (grade >3) due to neoadjuvant treatment were observed in 45.1% of the patients (n = 23/51), and major surgical complications occurred in 30.0% (n = 13/43), with no mortality noted. The intention-to-treat analysis showed that the 3-year overall survival rate was 54.7%, with a median survival time of 39.4 months, and a significant difference in overall survival was not observed between the FOLFIRINOX and GEM/nab-PTX groups. CONCLUSIONS: These results indicate that neoadjuvant chemotherapy with FOLFIRINOX or GEM/nab-PTX is feasible and well tolerated, achieving an R0 resection rate of 67.4%. The survival of patients was even found to be favorable in the intention-to-treat analysis.
|
Authors | Junpei Yamaguchi, Yukihiro Yokoyama, Tsutomu Fujii, Suguru Yamada, Hideki Takami, Hiroki Kawashima, Eizaburo Ohno, Takuya Ishikawa, Osamu Maeda, Hiroshi Ogawa, Yasuhiro Kodera, Masato Nagino, Tomoki Ebata |
Journal | Annals of surgery
(Ann Surg)
Vol. 275
Issue 6
Pg. 1043-1049
(06 01 2022)
ISSN: 1528-1140 [Electronic] United States |
PMID | 35258510
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Albumins
- folfirinox
- Oxaliplatin
- Deoxycytidine
- Irinotecan
- Paclitaxel
- Leucovorin
- Fluorouracil
|
Topics |
- Albumins
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Deoxycytidine
(therapeutic use)
- Fluorouracil
- Humans
- Irinotecan
- Leucovorin
- Neoadjuvant Therapy
(methods)
- Oxaliplatin
- Paclitaxel
(therapeutic use)
- Pancreatic Neoplasms
(drug therapy, surgery)
- Pancreatic Neoplasms
|